COVID-19 vaccine trials: promising advances
Compartir :
The Lancet, the world's most recognized medical journal, published the results of a trial of China's COVID-19 vaccine on May 22, the first vaccine of its kind to reach a phase 1 clinical trial. Testing by 21 Chinese researchers revealed that the vectorized adenovirus vaccine COVID-19 (Ad5-nCov) was safe, well tolerated by patients, and capable of eliciting an immune response against COVID-19 in humans.
The open test of 108 healthy adults shows promising results after 28 days and the final results will be evaluated within six months. Additional tests are needed to determine if the immune response it generates would effectively protect against COVID-19 infection. The research results allow further studies to be carried out on the development of the vectorized adenovirus vaccine COVID-19 (Ad5-nCov) to control the spread of COVID-19. The ongoing phase II trial (NCT04341389) in China will provide further information on the safety and immunogenicity of the vectorized adenovirus vaccine COVID-19 (Ad5-nCov).
Richard Horton, editor-in-chief of The Lancet, shared this progress via social media, saying the world's first clinical trial of the COVID-19 vaccine is safe, well tolerated, and can elicit a rapid immunity reaction. "These results represent an important milestone."
The coronavirus health crisis continues to devastate countries around the world. As the European countries and the states of EE. USA They begin to reopen, the virus is still in full swing in other countries, with South America and Russia as new epicenters of the disease. Even China has blocked another region due to concerns about COVID-19, and experts warn that a second wave is inevitable. The World Health Organization (WHO) has said that COVID-19 may be here to stay, but it is not as bad as it sounds. An increasing number of therapies have yielded positive results, and researchers are quickly finding two other treatment pathways that might work.
Modern America produced the first results of Phase 1 tests, but the company has come under fire for publishing partial data rather than a full study.
The CanSino results published in the medical journal The Lancet detail the results of the first phase of the study. The drug was able to elicit the desired immune response as early as 14 days after injection, the researchers found the type of neutralizing antibody. These are antibodies that can bind to the cutting-edge protein in COVID-19 and prevent it from infecting cells. Neutralizing antibodies increased significantly at 14 days and peaked at 28 days after vaccination. T cell response peaked 14 days after injection.
Regarding safety, the researchers detailed several symptoms, but they were all mild. The most common was pain at the injection site. The most common systemic side effects were fever, fatigue, headache, and muscle pain. No side effects were observed after 28 days of vaccination, and those reported were mild or moderate. One participant in the high-dose group developed high fever, fatigue, shortness of breath, and muscle pain, but the effects only lasted 48 hours.
This is great news, but it is important to note that these are only the results of Phase 1, and there are no guarantees yet.
"These results represent an important step. The trial shows that a single dose of the new vectorized adenovirus vaccine COVID-19 (Ad5-nCoV) produces virus and T-lymphocyte-specific antibodies within 14 days, making it a potential candidate for further investigation, "he said. Professor at the Beijing Biotechnology Institute, Wei Chen, in a statement. "However, the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19 and we are still far from this vaccine. accessible to all."
A mid-term trial of the vaccine is already underway in Wuhan, Reuters reports.
The CanSino coronavirus drug is on Morgan Stanley's restricted list of six promising COVID-19 vaccines that are most likely to work alongside candidates for Moderna, Oxford, and other drugs in clinical trials. A single vaccine may not be enough to meet the needs of the world.
Compartir :